Follow The Filings

MDGL Madrigal Pharmaceuticals Inc.

Health Care, filed as MADRIGAL PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 3 managers in 2026 Q2

  • 3 Owners
  • Max 27.9%
  • $723M
  • 2 reduce 1 exit

In 2026 Q2 John Paulson and Ron Baron trimmed Madrigal Pharmaceuticals, and Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 27.9% (John Paulson, Paulson & Co.). Not free-float ownership.

  1. John Paulson Reduce 27.9%
  2. Palo Alto Investors 0.13%

Who owns MDGL

Sorted by value, long equity only, as of 2026 Q2.

History
John Paulson, Paulson & Co. 27.9% Reduce −3.7% 1,340,020 $720M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01% Reduce −15.1% 4,500 $2.4M History
Palo Alto Investors 0.13% Hold 1,787 $960K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 3,319 $1.7M History

3 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MDGL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MDGL insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $61.5M sold by 8 insiders under 10b5-1 plans
  1. William John Sibold CEO
    Planned sale
    $2.8M 5,221 shares at $542.39 2.6% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  2. David Soergel Chief Medical Officer
    Planned sale
    $517K 1,042 shares at $495.74 9.4% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  3. Richard S Levy Director
    Planned sale
    $2.9M 5,682 shares at $515.44 21% of stake
    Traded May 22 Filed May 22
    ↗
  4. Mardi Dier CFO
    Planned sale
    $575K 1,336 shares at $430.36 9.7% of stake
    Traded Mar 6 Filed Mar 6
    ↗
  5. Carole Huntsman Chief Commercial Officer
    Planned sale
    $282K 570 shares at $494.59 5.9% of stake
    Traded Jan 26 Filed Jan 26
    ↗
  6. Shannon T Kelley General Counsel
    Planned sale
    $215K 429 shares at $501.40 4.8% of stake
    Traded Jan 20 Filed Jan 20
    ↗
  7. Paul A Friedman Director
    Planned sale
    $154K 280 shares at $551.24 0.1% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  8. Paul A Friedman Director
    Planned sale
    $12.8M 24,520 shares at $522.39 12% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  9. Rebecca Taub Director
    Planned sale
    $132K 240 shares at $550.33 0.1% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  10. Rebecca Taub Director
    Planned sale
    $9.6M 18,410 shares at $522.40 3.9% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  11. Paul A Friedman Director
    Planned sale
    $13.7M 24,800 shares at $552.18 12% of stake
    Traded Dec 10, 2025 Filed Dec 12, 2025
    ↗
  12. Rebecca Taub Director
    Planned sale
    $10.3M 18,650 shares at $552.15 3.9% of stake
    Traded Dec 10, 2025 Filed Dec 12, 2025
    ↗
  13. Mardi Dier CFO
    Planned sale
    $2.4M 4,173 shares at $578.34 29% of stake
    Traded Dec 2, 2025 Filed Dec 3, 2025
    ↗
  14. Carole Huntsman Chief Commercial Officer
    Planned sale
    $590K 1,064 shares at $554.91 9.6% of stake
    Traded Nov 21, 2025 Filed Nov 21, 2025
    ↗
  15. Richard S Levy Director
    Planned sale
    $4.4M 8,500 shares at $520.96 29% of stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 39 sales to cover taxes, 14 stock grants, 13 option exercises, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $180.13M $958.4M
Gross profit * — $173.9M —
Gross margin * — 96.5% —
Net income -$373.63M -$465.89M -$288.28M
Net margin * — -258.6% -30.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.637B $1.03B $1.25B
Total non-current assets * $3.27M $9.32M $13.82M
Total assets $0.641B $1.04B $1.26B
Total current liabilities $118.55M $169.28M $310.29M
Total non-current liabilities $116.67M $118.59M $346.61M
Total equity $405.33M $754.38M $602.69M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$324.23M -$455.57M -$189.55M
Cash from investing -$502.52M -$274.39M $32.32M
Cash from financing $595.12M $735.06M $255.98M
Net change in cash -$231.63M $5.1M $98.76M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf